Recombinant ADAMTS13 (rADAMTS13) therapy showed anti-inflammatory and antithrombotic effects [118] on preclinical models of cerebrovascular disease and TTP [119–123]. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.